NO753676L - - Google Patents
Info
- Publication number
- NO753676L NO753676L NO753676A NO753676A NO753676L NO 753676 L NO753676 L NO 753676L NO 753676 A NO753676 A NO 753676A NO 753676 A NO753676 A NO 753676A NO 753676 L NO753676 L NO 753676L
- Authority
- NO
- Norway
- Prior art keywords
- cat
- virus
- vaccine
- plague
- plague virus
- Prior art date
Links
- 241000282326 Felis catus Species 0.000 claims description 142
- 241000700605 Viruses Species 0.000 claims description 136
- 206010035148 Plague Diseases 0.000 claims description 69
- 241000607479 Yersinia pestis Species 0.000 claims description 69
- 229960005486 vaccine Drugs 0.000 claims description 55
- 241000282324 Felis Species 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 36
- 238000012546 transfer Methods 0.000 claims description 29
- 208000000655 Distemper Diseases 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 238000011534 incubation Methods 0.000 claims description 11
- 230000003053 immunization Effects 0.000 claims description 10
- 230000005540 biological transmission Effects 0.000 claims description 8
- 210000002345 respiratory system Anatomy 0.000 claims description 8
- 239000002054 inoculum Substances 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 5
- 230000003313 weakening effect Effects 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 206010037742 Rabies Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 12
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 210000001331 nose Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000027950 fever generation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 244000084743 Priva lappulacea Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- -1 dextrose and lactose Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/819—Viral vaccine for feline species, e.g. cats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/525,689 US3944469A (en) | 1974-11-21 | 1974-11-21 | Feline calicivirus vaccine and production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO753676L true NO753676L (US20100154141A1-20100624-C00001.png) | 1976-05-24 |
Family
ID=24094242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO753676A NO753676L (US20100154141A1-20100624-C00001.png) | 1974-11-21 | 1975-11-03 |
Country Status (17)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287178A (en) * | 1974-03-25 | 1981-09-01 | Pitman-Moore, Inc. | Feline rhinotracheitis vaccine and production and use thereof |
| ES486442A0 (es) * | 1978-11-30 | 1980-12-16 | Wellcome Found | Un metodo de preparar una vacuna que contiene una cepa ate- nuada de virus de peritonitis infecciosa felina. |
| US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
| US4303645A (en) * | 1980-04-18 | 1981-12-01 | Cornell Research Foundation, Inc. | Modified living canine parvovirus vaccine |
| US4537769A (en) * | 1982-04-06 | 1985-08-27 | American Cyanamid Company | Stabilization of influenza virus vaccine |
| US4522810A (en) * | 1982-12-09 | 1985-06-11 | The Regents Of The University Of California | Feline calicivirus vaccine |
| US5374424A (en) * | 1986-10-03 | 1994-12-20 | Miles Inc. | Multivalent felv-infected feline vaccine |
| AU661106B2 (en) * | 1992-02-28 | 1995-07-13 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-feline calicivirus recombinant antibody and gene fragment encoding the same |
| AU5329300A (en) | 1999-06-10 | 2001-01-02 | Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
| EP1606391B1 (en) * | 2003-03-14 | 2011-01-19 | Regents of the University of California | Virulent systemic feline calicivirus |
| US7309495B2 (en) * | 2003-03-14 | 2007-12-18 | The Regents Of The University Of California | Hemorrhagic feline calicivirus |
| US7306807B2 (en) * | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
| CN101563096A (zh) * | 2005-07-28 | 2009-10-21 | 辉瑞产品公司 | 疫苗施用方法、新猫杯状病毒、及抗猫细小病毒和猫疱疹病毒的动物免疫方法 |
| CA2681183A1 (en) * | 2007-05-30 | 2008-12-11 | Wyeth | Raccoon poxvirus expressing genes of feline antigens |
| WO2017106079A1 (en) | 2015-12-14 | 2017-06-22 | Boehringer Ingelheim Vetmedica, Inc. | Hybrid core feline vaccines |
| CN114874997B (zh) * | 2022-05-26 | 2023-05-23 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 猫杯状病毒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1177635A (en) * | 1966-02-18 | 1970-01-14 | Wellcome Found | Cell Stains. |
-
1974
- 1974-11-21 US US05/525,689 patent/US3944469A/en not_active Expired - Lifetime
-
1975
- 1975-10-30 GB GB45026/75A patent/GB1522006A/en not_active Expired
- 1975-11-03 NO NO753676A patent/NO753676L/no unknown
- 1975-11-14 SE SE7512828A patent/SE7512828L/xx not_active Application Discontinuation
- 1975-11-17 CH CH1487975A patent/CH622702A5/de not_active IP Right Cessation
- 1975-11-17 DK DK516975AA patent/DK141339B/da unknown
- 1975-11-19 JP JP50138275A patent/JPS5173118A/ja active Pending
- 1975-11-19 AU AU86755/75A patent/AU508944B2/en not_active Expired
- 1975-11-20 FR FR7535498A patent/FR2291766A1/fr active Granted
- 1975-11-20 CA CA240,138A patent/CA1055844A/en not_active Expired
- 1975-11-20 DE DE19752552137 patent/DE2552137A1/de not_active Withdrawn
- 1975-11-20 BE BE162051A patent/BE835784A/xx unknown
- 1975-11-20 ZA ZA757294A patent/ZA757294B/xx unknown
- 1975-11-20 AT AT884975A patent/AT340584B/de active
- 1975-11-20 FI FI753274A patent/FI53593C/fi not_active IP Right Cessation
- 1975-11-21 NL NL7513644A patent/NL7513644A/xx not_active Application Discontinuation
- 1975-11-21 ES ES442892A patent/ES442892A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU508944B2 (en) | 1980-04-17 |
| ES442892A1 (es) | 1977-08-16 |
| BE835784A (fr) | 1976-05-20 |
| FI53593B (US20100154141A1-20100624-C00001.png) | 1978-02-28 |
| FR2291766B1 (US20100154141A1-20100624-C00001.png) | 1978-07-28 |
| DE2552137A1 (de) | 1976-05-26 |
| ZA757294B (en) | 1977-06-29 |
| AT340584B (de) | 1977-12-27 |
| DK516975A (US20100154141A1-20100624-C00001.png) | 1976-05-22 |
| CA1055844A (en) | 1979-06-05 |
| FI753274A (US20100154141A1-20100624-C00001.png) | 1976-05-22 |
| FR2291766A1 (fr) | 1976-06-18 |
| NL7513644A (nl) | 1976-05-25 |
| AU8675575A (en) | 1977-05-26 |
| DK141339C (US20100154141A1-20100624-C00001.png) | 1980-08-25 |
| SE7512828L (sv) | 1976-05-24 |
| GB1522006A (en) | 1978-08-23 |
| JPS5173118A (US20100154141A1-20100624-C00001.png) | 1976-06-24 |
| CH622702A5 (US20100154141A1-20100624-C00001.png) | 1981-04-30 |
| FI53593C (fi) | 1978-06-12 |
| DK141339B (da) | 1980-02-25 |
| ATA884975A (de) | 1977-04-15 |
| US3944469A (en) | 1976-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100444809B1 (ko) | 저병원성생균백신및그제조방법 | |
| DE69522984T2 (de) | Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins | |
| NO753676L (US20100154141A1-20100624-C00001.png) | ||
| US3937812A (en) | Feline calicivirus vaccine and production thereof | |
| DK162421B (da) | Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen | |
| CN103347534A (zh) | 牛病毒性腹泻病毒1b型疫苗组合物和方法 | |
| CA1184115A (en) | Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines | |
| US4571386A (en) | Feline infectious peritonitis vaccine | |
| Furuuchi et al. | Effect of ambient temperatures on multiplication of attenuated transmissible gastroenteritis virus in the bodies of newborn piglets | |
| NO159782B (no) | Anordning ved fjaersystem, foerst og fremst paa kjoeretoeyer. | |
| KR100531491B1 (ko) | 백신으로서 소 호흡 코로나바이러스 | |
| Castrucci et al. | A study of cytopathic rotavirus strains isolated from calves with acute enteritis | |
| Matumoto et al. | Bovine respiratory syncytial virus: host range in laboratory animals and cell cultures | |
| CN114901293B (zh) | 用于预防或治疗幼小的哺乳动物得与黏膜相关的传染性疾病的血清组成物的制造方法、通过该方法制造的血清组成物及其用途 | |
| Taylor et al. | Studies on the pathogenesis of rinderpest in experimental cattle: III. Proliferation of an attenuated strain in various tissues following subcutaneous inoculation | |
| CN111849924B (zh) | 类nadc30猪蓝耳病强毒株、弱毒株及其应用 | |
| US4287178A (en) | Feline rhinotracheitis vaccine and production and use thereof | |
| CN112807424A (zh) | 牛病毒性腹泻、牛传染性鼻气管炎二联活疫苗及其制备方法 | |
| McKercher | A Comparison of the Viruses of Infectious Bovine Rhinotracheitis (IBR), Infectious Pustular Vulvovaginitis (IPV), and Rinderpest: Part I. Studies of Antigenic Relationships | |
| IE44691B1 (en) | Feline distempr vaccine | |
| Duncan | Biological and serological properties of Frater virus—a cytopathogenic agent associated with aseptic meningitis | |
| JPS6244528B2 (US20100154141A1-20100624-C00001.png) | ||
| CA1184116A (en) | Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines | |
| SU734279A1 (ru) | Вакцинный штамм в вируса N 5 вгнки | |
| Hirasawa et al. | Characterization of Low‐virulent Mouse Coronavirus Isolated from Faeces in a Mouse Colony |
